Relay Therapeutics, Inc 8-K, filed May 27, 2022
Relay Therapeutics, Inc. (RLAY)
About this 8-K
Relay Therapeutics, Inc filed this 8-K on May 27, 2022.
Items reported
- Item 5.03: Charter or bylaw amendment, or fiscal year change
- Item 5.07: Shareholder vote results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On May 27, 2022, Relay Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 150,000,000 shares to 300,000,000 shares. The increase in the number of authorized shares was approved by the holders of a majority of the outstanding shares of common stock of the Company at its annual meeting, as described in Item 5.07 below.
The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Certificate of Amendment, a copy of which is filed with this report as Exhibit 3.1 and is incorporated into this report by reference.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 27, 2022, the Company held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”) to consider and vote on the five proposals set forth below, each of which is described in detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 14, 2022. The final voting results are set forth below.
Proposal 1. Election of directors.
The Company’s stockholders elected each of the following individuals to serve as class II directors for a three-year term ending at the Company’s 2025 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows:
Name |
|
Votes For |
|
Votes Withheld |
|
Broker Non-Votes |
Alexis Borisy |
|
56,616,663.04 |
|
35,194,356.10 |
|
6,592,067.00 |
Mark Murcko, Ph.D. |
|
78,595,708.04 |
|
13,215,311.10 |
|
6,592,067.00 |
Laura Shawver, Ph.D. |
|
60,543,706.04 |
|
31,267,313.10 |
|
6,592,067.00 |
Proposal 2. Non-binding advisory vote on executive compensation.
The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, with the votes cast as follows:
Votes For |
|
Votes Against |
|
Abstain |
|
Broker Non-Votes |
83,645,401.04 |
|
3,551,366.10 |
|
4,614,252.00 |
|
6,592,067.00 |
Proposal 3. Non-binding advisory vote on the frequency of future non-binding advisory votes on executive compensation.
The Company's stockholders approved, on a non-binding, advisory basis, to set the frequency of future non-binding advisory votes on the compensation of the Company's named executive officers, to every one year, with the votes cast as follows:
One Year |
|
Two Years |
|
Three Years |
|
Abstain |
|
Broker Non-Votes |
86,491,256.04 |
|
9,024.00 |
|
77,927.10 |
|
5,232,812.00 |
|
6,592,067.00 |
Proposal 4. Approval of amendment to the Company's Fourth Amended and Restated Certificate of Incorporation.
The Company's stockholders approved an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares, with the votes cast as follows:
Votes For |
|
Votes Against |
|
Abstain |
|
Broker Non-Votes |
93,032,987.04 |
|
758,293.10 |
|
4,611,806.00 |
|
0.00 |
Proposal 5. Ratification of appointment of independent registered public accounting firm.
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022, with the votes cast as follows:
Votes For |
|
Votes Against |
|
Abstain |
|
Broker Non-Votes |
93,772,475.04 |
|
15,739.10 |
|
4,614,872.00 |
|
0.00 |
No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
3.1 |
|
104 |
Cover Page Interactive Data File (embedded within Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
RELAY THERAPEUTICS, INC. |
|
|
|
|
Date: |
May 27, 2022 |
By: |
/s/ Brian Adams |
|
|
|
Brian Adams, J.D. |
Exhibit 3.1
CERTIFICATE OF AMENDMENT
OF
FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
RELAY THERAPEUTICS, INC.
Relay Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”),
DOES HEREBY CERTIFY:
RESOLVED, that the first paragraph of ARTICLE IV of the Fourth Amended and Restated Certificate of Incorporation is hereby replaced in its entirety to read as follows:
“The total number of shares of capital stock which the Corporation shall have authority to issue is 310,000,000 of which (i) three hundred million (300,000,000) shares shall be a class designated as common stock, par value $0.001 per share (the “Common Stock”), and (ii) ten million (10,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.001 per share (the “Undesignated Preferred Stock”).”
In Witness Whereof, this Certificate of Amendment has been executed by a duly authorized officer of the Corporation on this 27th day of May, 2022.
By: |
/s/ Sanjiv K. Patel |
Name: |
Sanjiv K. Patel |
Title: |
President and Chief Executive Officer |